KEYTRUDA Plus Chemo Met Primary Endpoint of Progression-Free Survival (PFS) for Advanced or Recurrent Endometrial Carcinoma Merck announced that the Phase 3 NRG-GY018 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination ...
Aetna considers pembrolizumab (Keytruda) medically necessary for treatment of the following indications: Ampullary adenocarcinoma - as a single agent for microsatellite instability-high (MSI-H), mismatch repair deficient (dMMR), or tumor mutational burden-high (TMB-H greater than or equal to 10 muta...
In the trial of 886 bladder cancer patients who were eligible for cisplatin or carboplatin-containing chemotherapy, the Keytruda-Padcev combination reduced the risk of death by 53% over chemo, according to a late-breaking ESMO abstract. The median overall survival (OS) result for combo r...
Primary efficacy outcome measures were OS as well as progression-free survival (PFS) and objective response rate (ORR) as assessed by blinded independent central review (BICR) using RECIST v1.1, modified to follow a maximum of 10 target lesions and a maximum of five target lesions per organ....
Table 1: Overall Survival of Efti + KEYTRUDA® versus standard-of-care IO, IO-IO, IO-chemo, and IO-IO-chemo therapies for first-line treatment of advanced non-small cell lung cancer patients with PD-L1 TPS ≥1% *NSQ=Non-squamous;SQ=Squamous ...
Patients on pembrolizumab alone had the lowest rates of serious adverse events (AEs) at 16.9%, followed by chemotherapy alone (69.3%), and pembrolizumab plus chemotherapy (73.2%). The most common AEs included nausea and fatigue. Overall, 22% of patients experienced immune-related toxicities, Tabe...
The study also showed that the 1-year overall survival rate was 81.6%. However, Rosenberg was quick to note that the trial was only a 45-patient trial and that the trial needed to be expanded to see how more patients with metastatic urothelial carcinoma responded to the treatment. More...